Selective androgen receptor degrader
A selective androgen receptor degrader or downregulator (SARD) is a type of drug which interacts with the androgen receptor (AR) such that it causes the AR to be degraded and thus downregulated.[1] They are under investigation for the treatment of prostate cancer and other androgen-dependent conditions.[1]
Not to be confused with Selective androgen receptor modulator.
As of 2017, dimethylcurcumin (ASC-J9), a SARD, is under development for the treatment of acne vulgaris.[2]
See also
References
- Lai, AC; Crews, CM (25 November 2016). "Induced protein degradation: an emerging drug discovery paradigm". Nature Reviews. Drug Discovery. 16 (2): 101–114. doi:10.1038/nrd.2016.211. PMC 5684876. PMID 27885283.
- "ASCJ 9 - AdisInsight".
Androgen receptor modulators | |||||||
|---|---|---|---|---|---|---|---|
| AR |
| ||||||
| GPRC6A |
| ||||||
| |||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.